-
Company Insights
New![]()
Innovation and Patenting activity of Intellia Therapeutics Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Intellia Therapeutics Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Track & Monitor
![]()
Innovation in pharma: CRISPR nucleases
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s CRISPR nucleases innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and experience in...
-
Track & Monitor
![]()
Innovation in pharma: gene splicing nucleases
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s gene splicing nucleases innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and experience...
-
Company Profile
![]()
Intellia Therapeutics Inc – Company Profile
Intellia Therapeutics Inc (Intellia Therapeutics) is a biotechnology company. The company developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. It develops in vivo programs for the treatment of liver diseases such as alpha-1 antitrypsin deficiency, and primary hyperoxaluria Type 1. Intellia Therapeutics also develops ex vivo programs such as hematopoietic stem cells (HSCs) and chimeric antigen receptor T cells (CAR-T cells). The company’s pipeline products include OTQ923 / HIX763, NTLA-5001. The company conducts genome...
Add to Basket -
Thematic Analysis
![]()
Precision and Personalized Medicine in Pharma – Thematic Intelligence
Precision and Personalized Medicine in Pharma Thematic Report Overview Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space. The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology,...
-
Product Insights
![]()
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hereditary Angioedema (HAE) Pipeline Drugs Development Market Overview Hereditary Angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids. The Hereditary Angioedema pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hereditary Angioedema, complete with analysis by...
-
Product Insights
![]()
Net Present Value Model: NTLA-2001
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model NTLA-2001 Drug Details NTLA-2001 is under...
-
Product Insights
![]()
Net Present Value Model: NTLA-2002
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model NTLA-2002 Drug Details NTLA-2002 is under...
-
Track & Monitor
![]()
Innovation in Pharmaceuticals: Mammalian expression vectors
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Track & Monitor
![]()
Innovation in Pharmaceuticals: Cell therapy for ocular disorders
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.